Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
Jenna E Januszka, Emily N Drwiega, Melissa E Badowski University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USACorrespondence: Melissa E Badowski, Clinical Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-11-01
|
| Series: | HIV/AIDS: Research and Palliative Care |
| Subjects: | |
| Online Access: | https://www.dovepress.com/bictegraviremtricitabinetenofovir-alafenamide-for-hiv-1-what-is-the-hi-peer-reviewed-fulltext-article-HIV |
| _version_ | 1797447414593880064 |
|---|---|
| author | Januszka JE Drwiega EN Badowski ME |
| author_facet | Januszka JE Drwiega EN Badowski ME |
| author_sort | Januszka JE |
| collection | DOAJ |
| description | Jenna E Januszka, Emily N Drwiega, Melissa E Badowski University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USACorrespondence: Melissa E Badowski, Clinical Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Rm 164, M/C 886, Chicago, IL, 60612, USA, Email badowski@uic.eduAbstract: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet antiretroviral therapy regimen. B/F/TAF has become a popular treatment choice because of its small tablet size, high barrier to resistance, favorable tolerability, and limited drug–drug interaction profile. Continued research on B/F/TAF has revealed additional potential for this regimen. This review presents recent literature supporting the use of B/F/TAF as an option for consolidating therapy and maintaining virologic suppression in individuals despite M184V/I mutations. Additionally, children are a unique patient population with limited antiviral options. Standard dose B/F/TAF has demonstrated similar drug exposure in children and adolescents as adults, and low-dose B/F/TAF is approved for children living with HIV greater than two years of age and weighing at least 14 kg. Data supporting this recommendation is described in this review. Finally, despite a lack of prospective data, B/F/TAF may have a role in the future of pre- and post-exposure prophylaxis. This review discusses these discoveries and the continued exploration of the hidden potential of B/F/TAF.Keywords: Biktarvy, bictegravir, INSTI, HIV |
| first_indexed | 2024-03-09T13:55:32Z |
| format | Article |
| id | doaj.art-e9a677cf88cb42fea143259f008608b2 |
| institution | Directory Open Access Journal |
| issn | 1179-1373 |
| language | English |
| last_indexed | 2024-03-09T13:55:32Z |
| publishDate | 2023-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | HIV/AIDS: Research and Palliative Care |
| spelling | doaj.art-e9a677cf88cb42fea143259f008608b22023-11-30T18:44:06ZengDove Medical PressHIV/AIDS: Research and Palliative Care1179-13732023-11-01Volume 1570571188588Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?Januszka JEDrwiega ENBadowski MEJenna E Januszka, Emily N Drwiega, Melissa E Badowski University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USACorrespondence: Melissa E Badowski, Clinical Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Rm 164, M/C 886, Chicago, IL, 60612, USA, Email badowski@uic.eduAbstract: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet antiretroviral therapy regimen. B/F/TAF has become a popular treatment choice because of its small tablet size, high barrier to resistance, favorable tolerability, and limited drug–drug interaction profile. Continued research on B/F/TAF has revealed additional potential for this regimen. This review presents recent literature supporting the use of B/F/TAF as an option for consolidating therapy and maintaining virologic suppression in individuals despite M184V/I mutations. Additionally, children are a unique patient population with limited antiviral options. Standard dose B/F/TAF has demonstrated similar drug exposure in children and adolescents as adults, and low-dose B/F/TAF is approved for children living with HIV greater than two years of age and weighing at least 14 kg. Data supporting this recommendation is described in this review. Finally, despite a lack of prospective data, B/F/TAF may have a role in the future of pre- and post-exposure prophylaxis. This review discusses these discoveries and the continued exploration of the hidden potential of B/F/TAF.Keywords: Biktarvy, bictegravir, INSTI, HIVhttps://www.dovepress.com/bictegraviremtricitabinetenofovir-alafenamide-for-hiv-1-what-is-the-hi-peer-reviewed-fulltext-article-HIVbiktarvybictegravirinstihiv |
| spellingShingle | Januszka JE Drwiega EN Badowski ME Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? HIV/AIDS: Research and Palliative Care biktarvy bictegravir insti hiv |
| title | Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? |
| title_full | Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? |
| title_fullStr | Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? |
| title_full_unstemmed | Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? |
| title_short | Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? |
| title_sort | bictegravir emtricitabine tenofovir alafenamide for hiv 1 what is the hidden potential of this emerging treatment |
| topic | biktarvy bictegravir insti hiv |
| url | https://www.dovepress.com/bictegraviremtricitabinetenofovir-alafenamide-for-hiv-1-what-is-the-hi-peer-reviewed-fulltext-article-HIV |
| work_keys_str_mv | AT januszkaje bictegraviremtricitabinetenofoviralafenamideforhiv1whatisthehiddenpotentialofthisemergingtreatment AT drwiegaen bictegraviremtricitabinetenofoviralafenamideforhiv1whatisthehiddenpotentialofthisemergingtreatment AT badowskime bictegraviremtricitabinetenofoviralafenamideforhiv1whatisthehiddenpotentialofthisemergingtreatment |